Table 3.
Mortality risk based on presence of T2D and VFs at baseline, stratified by sex and BMI category
| Outcome: death during follow-up, HR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|
| Overall (N = 19,822) | Men (N = 4,405) | Women (N = 15,417) | |||||
| Normal weight (N = 1,413) | Overweight (N = 2,323) | Obese (N = 643) | Normal weight (N = 5,747) | Overweight (N = 6,318) | Obese (N = 3,204) | ||
| Without T2D or VFs (reference) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| With VFs alone | 1.20 (1.13– 1.27) | 1.09 (0.81–1.45) | 1.03 (0.81–1.31) | 1.08 (0.59–1.94) | 1.26 (1.15–1.39) | 1.24 (1.13–1.36) | 1.15 (1.01–1.32) |
| With T2D alone | 1.78 (1.65–1.91) | 1.84 (1.44–2.36) | 1.50 (1.21–1.84) | 1.22 (0.83–1.78) | 1.64 (1.39–1.95) | 2.04 (1.79–2.32) | 1.87 (1.62–2.15) |
| With both T2D and VFs | 2.05 (1.73–2.43) | 1.27 (0.46–3.48) | 2.42 (1.20– 4.88) | 3.11 (1.50–6.46) | 1.75 (1.23–2.47) | 2.32 (1.73–3.11) | 1.92 (1.37–2.68) |
| With T2D alone (reference) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| With both T2D and VFs | 1.21 (0.97–1.49) | 0.68 (0.24–1.93) | 1.61 (0.78–3.33) | 2.54 (1.17–5.51) | 1.06 (0.72–1.55) | 1.13 (0.82–1.55) | 1.03 (0.72–1.45) |
| With VFs alone (reference) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| With both T2D and VFs | 1.71 (1.43–2.03) | 1.15 (0.4–3.24) | 2.38 (1.15–4.96) | 3.1 (1.25–7.57) | 1.37 (0.97–1.95) | 1.86 (1.38–2.52) | 1.65 (1.16–2.34) |
Individuals were assigned at baseline to four groups: without T2D or VFs, with T2D only, with VFs only, and with both T2D and VFs. A Cox regression model adjusted for age (natural splines with 5 df), corticosteroid use, antiosteoporotic treatment, and cohort, stratified for sex and BMI, was fitted to estimate the survival of the individuals based on their T2D and VF status at baseline.